Skandinaviska Enskilda Banken Ab (Publ) Protagonist Therapeutics, Inc Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $19.9 Billion
- Q1 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 248,950 shares of PTGX stock, worth $12.7 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
248,950
Previous 310,650
19.86%
Holding current value
$12.7 Million
Previous $12 Million
0.4%
% of portfolio
0.06%
Previous 0.06%
Shares
7 transactions
Others Institutions Holding PTGX
# of Institutions
304Shares Held
61.4MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$312 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$294 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$292 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$218 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$153 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.51B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...